Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an alternative to standard-of-care eye injections needed as often as once a monthBy
Investegate announcements from F. Hoffmann-La Roche Ltd, FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD)
Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and are now in line with the prior year for
Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.Collaboration with PathAI
Investegate announcements from F. Hoffmann-La Roche Ltd, US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer